Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.

about

Oral anti-pseudomonal antibiotics for cystic fibrosis A Method for Efficient Loading of Ciprofloxacin Hydrochloride in Cationic Solid Lipid Nanoparticles: Formulation and Microbiological Evaluation.

P2860

Q26471106-A8FA145A-FCD7-43AC-B03C-26547112D95E Q55262718-828C7F64-561C-4672-965C-ADC07B05D7AB

P2860

Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.

Item

http://www.wikidata.org/entity/Q41015058

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Ciprofloxacin during upper res ...... ystic fibrosis: a pilot study.

@en

type

Item

label

Ciprofloxacin during upper res ...... ystic fibrosis: a pilot study.

@en

prefLabel

Ciprofloxacin during upper res ...... ystic fibrosis: a pilot study.

@en

P1476

Ciprofloxacin during upper res ...... ystic fibrosis: a pilot study.

@en

P2093

Amanda Harris

http://www.w3.org/2001/XMLSchema#string

Ann Dewar

http://www.w3.org/2001/XMLSchema#string

Julian P Legg

http://www.w3.org/2001/XMLSchema#string

Katharine C Pike

http://www.w3.org/2001/XMLSchema#string

Katrina Cathie

http://www.w3.org/2001/XMLSchema#string

Keith Foote

http://www.w3.org/2001/XMLSchema#string

P2860

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Effects of upper respiratory tract infections in patients with cystic fibrosis.

Influenza-associated cystic fibrosis pulmonary exacerbations.

Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis

Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling.

Lung inflammation as a therapeutic target in cystic fibrosis.

RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells.

Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner.

P304

272-280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753465815601571

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Saul N Faust

Gary Connett

P577

2015-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26341118

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.

about

P2860

P2860

Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921